NCT05776121View on ClinicalTrials.gov

Study of ZB001 in Chinese Patients With Thyroid Eye Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

April 17, 2024

Study Completion Date

April 17, 2024

Conditions
Thyroid Eye Disease
Interventions
DRUG

ZB001 for injection

Dose Cohort1 (3 mg/kg) ZB001 four IV injections

DRUG

ZB001 for injection

Dose Cohort2 (10 mg/kg) ZB001 four IV injections

Trial Locations (9)

100730

Peking Union Medical College Hospital, Beijing

Unknown

Beijing Tongren Hospital, CMU, Beijing

Peking University Third Hospital, Beijing

Third Xiangya Hospital of Central South University, Changsha

Xiangya Hospital Central South University, Changsha

Chongqing Aier General Hospital, Chongqing

The Second Hosptial of Dalian Medical University, Dalian

The Second Hosptial of Anhui Medical University, Hefei

Affiliated Eye Hospital of Nanchang University, Nanchang

All Listed Sponsors
lead

Zenas BioPharma (USA), LLC

INDUSTRY

NCT05776121 - Study of ZB001 in Chinese Patients With Thyroid Eye Disease | Biotech Hunter | Biotech Hunter